Cannabidiol as a Potential Treatment for Anxiety Disorders. Blessing E.M.; Steenkamp M.M.; Manzanares J.; Marmar C.R. Neurotherapeutics, 2015, 12, 4, 825-36 doi:10.1007/s13311-015-0387-1 (ISSN: 1878-7479) Abstract : Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD's potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, [...]
Lire la suiteCannabidiol in Anxiety and Sleep : A Large Case Series Scott Shannon, Nicole Lewis, Heather Lee, Shannon Hughes, The Permanente Journal, 2019, 23, 18-041 doi.org/10.7812/TPP/18-041 ABSTRACT Context : Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a “high.” A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical [...]
Lire la suitePharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy James W. Wheless, · Dennis Dlugos, · Ian Miller, · D. Alexander Oh, · Neha Parikh, · Steven Phillips, · J. Ben Renfroe, · Colin M. Roberts, · Isra Saeed, · Steven P. Sparagana, · Jin Yu, · Maria Roberta Cilio, on behalf of the INS011-14-029 Study Investigators CNS Drugs, 2019 https://doi.org/10.1007/s40263-019-00624-4 Abstract Background : Prior studies have evaluated the use of various constituents of cannabis for their anti-seizure effects. Specifically, cannabidiol, a non-psychoactive component of cannabis, has been investigated for treatment-resistant epilepsy, but more information is needed particularly on [...]
Lire la suiteCannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Arkell T.R., Lintzeris N., Kevin R.C., Ramaekers J.G., Vandrey R., Irwin C., Haber P.S., McGregor I.S. Psychopharmacology (Berlin), 2019 DOI : 10.1007/s00213-019-05246-8 PMID : 31044290 Abstract BACKGROUND : The main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), can impair driving performance. Cannabidiol (CBD), a non-intoxicating cannabis component, is thought to mitigate certain adverse effects of THC. It is possible then that cannabis containing equivalent CBD and THC will differentially affect driving and cognition relative to THC-dominant cannabis. AIMS : The present study investigated and compared the effects of THC-dominant and [...]
Lire la suiteDoes cannabidiol protect against adverse psychological effects of THC ? Raymond J. M. Niesink and Margriet W. van Laar Frontiers in Psychiatry, 2013, 4, 130 doi : 10.3389/fpsyt.2013.00130. Abstract The recreational use of cannabis can have persistent adverse effects on mental health. Delta 9-tetrahydro-cannabinol (THC) is the main psychoactive constituent of cannabis, and most, if not all, of the effects associated with the use of cannabis are caused by THC. Recent studies have suggested a possible protective effect of another cannabinoid, cannabidiol (CBD). A literature search was performed in the bibliographic databases PubMed, PsycINFO, andWeb of Science using the keyword “cannabidiol.” After removing duplicate entries, [...]
Lire la suiteLong-Term Stress and Concomitant Marijuana Smoke Exposure Affect Physiology, Behavior and Adult Hippocampal Neurogenesis Kitti Rusznák, Kata Csekö, Zsófia Varga, Dávid Csabai, Ágnes Bóna, Mátyás Mayer, Zsolt Kozma, Zsuzsanna Helyes and Boldizsár Czéh Frontiers in Pharmacology, 2018, 9, 786 doi: 10.3389/fphar.2018.00786. eCollection 2018 www.frontiersin.org Abstract Marijuana is a widely used recreational drug with increasing legalization worldwide for medical purposes. Most experimental studies use either synthetic or plant-derived cannabinoids to investigate the effect of cannabinoids on anxiety and cognitive functions. The aim of this study was to mimic real life situations where young people smoke cannabis regularly to relax from everyday stress. Therefore, we exposed young adult [...]
Lire la suiteDoes Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition Marco Colizzi & Sagnik Bhattacharyya Current Addiction Reports, 2017, 4, 62–74 DOI 10.1007/s40429-017-0142-2 Abstract Purpose of Review : The lack of clarity about the effect of cannabis use on cognition may be attributable to the considerable heterogeneity among studies in terms of cannabis composition. This article selectively reviews studies examining the distinctive effects of cannabinoids on human cognition, particularly those of delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). Recent Findings : Research indicates that Δ9-THC administration acutely impairs cognition, particularly memory and emotional processing. Limited evidence suggests that CBD administration might improve cognition in cannabis [...]
Lire la suiteCannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Amir Englund, Paul D Morrison, Judith Nottage, Dominic Hague, Fergus Kane1, Stefania Bonaccorso1, James M Stone, Avi Reichenberg, Rudolf Brenneisen, David Holt, Amanda Feilding, Lucy Walker, Robin M Murray and Shitij Kapur Journal of Psychopharmacology, 2012 Doi : 10.1177/0269881112460109 Abstract Community-based studies suggest that cannabis products that are high in Δ9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited [...]
Lire la suiteCannabidiol, a Cannabis sativa constituent, as an antipsychotic drug A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira and F.S. Guimarães Brazilian Journal of Medical and Biological Research, 2006, 39, 421-429 ISSN 0100-879X Review Abstract A high dose of Δ9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of Δ9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The [...]
Lire la suiteDissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity Matthew B. Wall, Rebecca Pope, Tom P. Freeman, Oliwia S. Kowalczyk, Lysia Demetriou, Claire Mokrysz, Chandni Hindocha, Will Lawn, Michael A.P. Bloomfield, Abigail M. Freeman, Amanda Feilding, David J. Nutt and H. Valerie Curran Journal of Psychopharmacology, 2019, 1–9 DOI: 10.1177/0269881119841568 journals.sagepub.com/home/jop Abstract Background : Two major constituents of cannabis are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the main psychoactive component; CBD may buffer the user against the harmful effects of THC. Aims : We examined the effects of two strains of cannabis and placebo on the human brain’s resting-state networks [...]
Lire la suite